Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ansan
Clinical trial register · South Korea

Clinical Trials in Ansan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
GlaxoSmithKline4 Novartis Pharmaceuticals3 Inha University Hospital2 Myungmoon Pharma. Co. Ltd.2 Pharmicell Co., Ltd.2
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Ansan

36 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
180
Ansan, Seoul
2026-08-24
Not yet open
Seoul National University Hospital
Not applicable
1,724
Ansan, Anyang, Busan, Changwon, Cheonan, Daegu, Gwangju, Incheon
2026-07-29
Not yet open
Nu Eyne Co., Ltd.
Not applicable
40
Ansan, Seoul
2026-07-09
Recruiting
SK Bioscience Co., Ltd.
Phase 3
780
Daegu, Ansan, Hwaseong-si, Seongnam-si, Incheon, Seoul
2026-07-04
Recruiting
LEXURE for Post-Stroke Aphasia
NCT07570264Aphasia
Nunaps Inc
Not applicable
116
Ansan, Busan, Chuncheon, Daegu, Gwangju, Ilsan, Jeonju, Seoul
2026-04-16
Not yet open
Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment
NCT07398001Percutaneous Coronary Intervention, Antiplatelet Therapy, Drug-coated Balloon
Ulsan University Hospital
Not applicable
1,042
Ansan, Chuncheon, Pusan, Seoul, Ulsan
2026-02-12
Not yet open
Inha University Hospital
Phase 4
1,898
Incheon, Ansan, Bucheon-si, Busan, Cheonan, Goyang, Goyang-si, Guri-si
2026-01-01
By invitation
Celldex Therapeutics
Phase 3
1,370
Ansan, Seoul, Suwon
2025-11-25
Recruiting
AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM
NCT07347691Embolic Stroke of Undetermined Source
Inha University Hospital
Observational
92
Ansan, Incheon, Jeju City, Seoul, Suwon
2025-11-19
Recruiting
Korea University Anam Hospital
Not applicable
400
Ansan, Seoul
2025-10-22
Recruiting
Myungmoon Pharma. Co. Ltd.
Phase 4
358
Ansan, Suwon, Busan, Gyeonggi-do, Incheon, Seoul
2025-08-29
Recruiting
HK inno.N Corporation
Phase 2
162
Ansan
2025-08-12
Recruiting
Myungmoon Pharma. Co. Ltd.
Phase 4
484
Ansan, Bucheon-si, Suwon, Busan, Daegu, Gyeonggi-do, Incheon, Seoul
2025-07-28
Active, closed
Aligos Therapeutics
Phase 2
200
Ansan, Busan, Seoul, Ulsan, Yangsan
2025-07-15
Recruiting
Incheon St.Mary's Hospital
Phase 4
160
Ansan, Busan, Chilgok, Chuncheon, Gwangju, Incheon, Seoul, Yangsan
2025-07-07
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Ansan, Seoul
2025-05-16
Recruiting
Samsung Medical Center
Not applicable
1,200
Ansan, Daegu, Gangneung, Goyang, Gwangju, Gwangmyeong, Incheon, Jeonju
2025-04-07
Active, closed
HanAll BioPharma Co., Ltd.
Phase 4
50
Ansan, Jeonju, Kwangju, Seongnam, Seoul, Suwon
2024-12-12
Active, closed
GlaxoSmithKline
Phase 2
283
Ansan, Busan, Pusan, Seoul
2024-11-11
Recruiting
Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke
NCT06649240Ischemic Stroke, Small Vessel Cerebrovascular Disease, Cholesterol, LDL, Secondary Prevention
DrugsBiweekly·Ezetimibe
Seoul National University Hospital
Not applicable
4,016
Ansan, Anyang, Busan, Changwon, Cheongju-si, Chuncheon, Daegu, Daejeon
2024-10-04
Recruiting
GlaxoSmithKline
Phase 2
393
Ansan, Bucheon-si, Daegu, Seoul, Suwon Gyeonggi-do
2024-09-27
Not yet open
Daewoong Pharmaceutical Co. LTD.
Phase 3
348
Ansan
2024-09-23
Active, closed
GlaxoSmithKline
Phase 3
10,212
Seoul, Ansan, Bucheon-si Kyunggi-do 14584, Daegu, Incheon, Jeonju, Kangwon-do, Suwon Gyeonggi-do
2024-08-01
Active, closed
Celldex Therapeutics
Phase 3
963
Seongdong, Ansan, Seongnam-si, Seoul, Suwon
2024-07-11
Recruiting
Seung-Jung Park
Not applicable
960
Seoul, Ansan, Anyang, Bucheon-si, Busan, Changwon, Chuncheon, Daegu
2024-04-25
Recruiting
A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants
NCT06246123Arthritis, Rheumatoid, Colitis, Ulcerative
Eisai Korea Inc.
Observational
2,040
Cheonan, Chuncheon, Wŏnju, Ansan, Bucheon-si, Goyang-si, Gwangmyeong, Seongnam-si
2024-02-27
Recruiting
Genexine, Inc.
Phase 3
429
Ansan, Incheon, Seoul
2024-01-25
Active, closed
Samsung Bioepis Co., Ltd.
Phase 1
163
Ansan, Busan, Daegu, Hwasun, Incheon, Jinju, Seongnam, Seoul
2024-01-16
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Ansan, Busan, Seoul
2023-11-15
Active, closed
GlaxoSmithKline
Phase 3
3,038
Ansan, Bucheon-si, Incheon, Kangwon-do, Seoul
2022-08-10
Active, closed
Drug-Coated Balloon in Patients With High Bleeding Risk
NCT05221931Coronary Artery Disease
Samsung Medical Center
Not applicable
1,359
Ansan, Cheongju-si, Daegu, Gangneung, Gwangju, Gwangmyeong, Incheon, Jinju
2022-07-29
Recruiting
Green Cross Corporation
Phase 2
230
Ansan
2022-07-05
Recruiting
Pharmicell Co., Ltd.
Observational
100
Ansan, Bucheon-si, Cheonan, Chuncheon, Gangneung-si, Seoul, Wŏnju, Yongin
2021-09-09
Recruiting
Pharmicell Co., Ltd.
Phase 3
200
Ansan, Bucheon-si, Cheonan, Chuncheon, Gangneung-si, Seoul, Wŏnju, Yongin
2021-04-19
Active, closed
Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery
NCT04585074Breast Neoplasms, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Benign Breast Disease
Severance Hospital
Observational
2,000
Busan, Sejong, Daegu, Wŏnju, Ansan, Goyang-si, Yongin-si, Changwon
2020-04-08
Active, closed
EHL Bio Co., Ltd.
Phase 2
118
Daejeon, Ansan, Seoul
2019-12-11
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/ansan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in Ansan.

How many clinical trials are recruiting in Ansan?

19 of the 36 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 5 have not yet opened recruitment, 11 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ansan), 36 studies
PhaseStudiesRecruitingShare
Phase 310427.8%
Not applicable9525%
Phase 27419.4%
Phase 45313.9%
Observational4311.1%
Phase 1102.8%

Most active sponsors

Lead sponsors with the most studies (Ansan)
Lead sponsorStudiesRecruiting
GlaxoSmithKline41
Novartis Pharmaceuticals32
Celldex Therapeutics20
Inha University Hospital21
Myungmoon Pharma. Co. Ltd.22
Pharmicell Co., Ltd.22
Samsung Medical Center21
Seoul National University Hospital21
Aligos Therapeutics10
Daewoong Pharmaceutical Co. LTD.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.